77 related articles for article (PubMed ID: 32817138)
21. Future directions in drug development in pancreatic cancer.
Lambert A; Conroy T; Ducreux M
Semin Oncol; 2021 Feb; 48(1):47-56. PubMed ID: 33674067
[TBL] [Abstract][Full Text] [Related]
22. Managing inoperable pancreatic cancer: the role of the pancreaticobiliary physician.
Yau CC; Leeds J
Frontline Gastroenterol; 2022; 13(e1):e88-e93. PubMed ID: 35812020
[TBL] [Abstract][Full Text] [Related]
23. Pancreatic cancer in 2021: What you need to know to win.
Tonini V; Zanni M
World J Gastroenterol; 2021 Sep; 27(35):5851-5889. PubMed ID: 34629806
[TBL] [Abstract][Full Text] [Related]
24. Current status of non-surgical treatment of locally advanced pancreatic cancer.
Spiliopoulos S; Zurlo MT; Casella A; Laera L; Surico G; Surgo A; Fiorentino A; de'Angelis N; Calbi R; Memeo R; Inchingolo R
World J Gastrointest Oncol; 2021 Dec; 13(12):2064-2075. PubMed ID: 35070042
[TBL] [Abstract][Full Text] [Related]
25. Metastatic Pancreatic Cancer: Where Are We?
Hernández-Blanquisett A; Quintero-Carreño V; Martínez-Ávila MC; Porto M; Manzur-Barbur MC; Buendía E
Oncol Rev; 2023; 17():11364. PubMed ID: 38304752
[TBL] [Abstract][Full Text] [Related]
26. New Treatment Options in Metastatic Pancreatic Cancer.
Fudalej M; Kwaśniewska D; Nurzyński P; Badowska-Kozakiewicz A; Mękal D; Czerw A; Sygit K; Deptała A
Cancers (Basel); 2023 Apr; 15(8):. PubMed ID: 37190255
[TBL] [Abstract][Full Text] [Related]
27. Clinical Applications of Classical and Novel Biological Markers of Pancreatic Cancer.
Pekarek L; Fraile-Martinez O; Garcia-Montero C; Saez MA; Barquero-Pozanco I; Del Hierro-Marlasca L; de Castro Martinez P; Romero-Bazán A; Alvarez-Mon MA; Monserrat J; García-Honduvilla N; Buján J; Alvarez-Mon M; Guijarro LG; Ortega MA
Cancers (Basel); 2022 Apr; 14(8):. PubMed ID: 35454771
[TBL] [Abstract][Full Text] [Related]
28. Risk factors for pancreatic adenocarcinoma and prospects for screening.
Decker GA; Batheja MJ; Collins JM; Silva AC; Mekeel KL; Moss AA; Nguyen CC; Lake DF; Miller LJ
Gastroenterol Hepatol (N Y); 2010 Apr; 6(4):246-54. PubMed ID: 20567579
[TBL] [Abstract][Full Text] [Related]
29. Surgical treatment options in a patient with borderline resectable tumour - a case report of a 54-year-old patient with locally advanced melanoma.
Ryguła A; Kowalski M; Stec P; Ziętek M
Postepy Dermatol Alergol; 2023 Feb; 40(1):178-180. PubMed ID: 36909894
[No Abstract] [Full Text] [Related]
30. Editorial: Emerging anti-cancer compounds and immunomodulators for pancreatic cancer treatment.
DelGiorno KE; Safe S; Bailey-Lundberg JM
Front Oncol; 2024; 14():1411836. PubMed ID: 38737907
[No Abstract] [Full Text] [Related]
31. First- and second-line treatment of metastatic pancreatic adenocarcinoma: the conundrum continues.
Philip PA
Gastrointest Cancer Res; 2009 Jan; 3(1):37-9. PubMed ID: 19343138
[No Abstract] [Full Text] [Related]
32. Optimal chemotherapy dosing in a bilateral lower extremities amputee with metastatic pancreatic adenocarcinoma.
Owen D; O'Reilly EM; Ang C; Ma J; Do RK; Abou-Alfa GK
Gastrointest Cancer Res; 2013 May; 6(3):93-4. PubMed ID: 23936551
[No Abstract] [Full Text] [Related]
33. Discussion: Current Multimodality Treatment Options in Pancreatic Cancer in Clinical Practice - What Is the Future Impact of Molecular Biological Profiling?
Kleger A; Ellenrieder V; Friess H; Michl P; Schneider M; Yang Y; Kornmann M
Visc Med; 2022 Feb; 38(1):49-55. PubMed ID: 35295897
[No Abstract] [Full Text] [Related]
34. Changes over time in the course of advanced pancreatic cancer treatment with systemic chemotherapy: a pooled analysis of five clinical trials from two decades of the German AIO study group.
Weiss L; Fischer LE; Heinemann V; Gieseler F; Hoehler T; Mayerle J; Quietzsch D; Reinacher-Schick A; Schenk M; Seipelt G; Siveke JT; Stahl M; Kaiser U; Waldschmidt DT; Dorman K; Zhang D; Westphalen CB; Boeck S; Haas M
ESMO Open; 2024 Apr; 9(4):102944. PubMed ID: 38503144
[TBL] [Abstract][Full Text] [Related]
35. Genomic insights and prognostic significance of novel biomarkers in pancreatic ductal adenocarcinoma: A comprehensive analysis.
Chen Y; Huang A; Bi Y; Wei W; Huang Y; Ye Y
Biochem Biophys Rep; 2024 Mar; 37():101580. PubMed ID: 38107664
[TBL] [Abstract][Full Text] [Related]
36. A Simple Overview of Pancreatic Cancer Treatment for Clinical Oncologists.
Garajová I; Peroni M; Gelsomino F; Leonardi F
Curr Oncol; 2023 Oct; 30(11):9587-9601. PubMed ID: 37999114
[TBL] [Abstract][Full Text] [Related]
37. Treatment sequences and prognostic/predictive factors in metastatic pancreatic ductal adenocarcinoma: univariate and multivariate analyses of a real-world study in Europe.
Taieb J; Seufferlein T; Reni M; Palmer DH; Bridgewater JA; Cubillo A; Prager GW; Vermeire A; Hédouin-Biville F; Teng Z; Macarulla T
BMC Cancer; 2023 Sep; 23(1):877. PubMed ID: 37723453
[TBL] [Abstract][Full Text] [Related]
38. The influence of procedural volume on short-term outcomes for robotic pancreatoduodenectomy-a cohort study and a learning curve analysis.
Kawka M; Gall TMH; Hand F; Nazarian S; Cunningham D; Nicol D; Jiao LR
Surg Endosc; 2023 Jun; 37(6):4719-4727. PubMed ID: 36890417
[TBL] [Abstract][Full Text] [Related]
39. Therapeutic advances in metastatic pancreatic cancer: a focus on targeted therapies.
Turpin A; Neuzillet C; Colle E; Dusetti N; Nicolle R; Cros J; de Mestier L; Bachet JB; Hammel P
Ther Adv Med Oncol; 2022; 14():17588359221118019. PubMed ID: 36090800
[TBL] [Abstract][Full Text] [Related]
40. Microsatellite instability and chemosensitivity in solid tumours.
Cherri S; Oneda E; Noventa S; Melocchi L; Zaniboni A
Ther Adv Med Oncol; 2022; 14():17588359221099347. PubMed ID: 35620236
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
